Also trades as: ROG.SW (SIX) · $vol 443M · ROP.SW (SIX) · $vol 436M · RO.SW (SIX) · $vol 13M · RHHVF (OTC) · $vol 2M · 0QQ6.L (LSE) · $vol 2M · RHHBF (OTC) · $vol 0M · ROG.TO (TSX) · $vol 0M
RHHBY OTC
Roche Holding AG
1W: +2.1%
1M: +13.1%
3M: +9.8%
YTD: +17.3%
1Y: +42.8%
3Y: +94.9%
5Y: +42.6%
$60.37
+0.39 (+0.65%)
Pre-Market: $60.30 (-0.06, -0.11%)
Weekly Expected Move ±3.7%
$57
$59
$61
$63
$66
Credit Risk of going bust: lower than 83% of companies Debt: 9.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.46 (down 99.2%), Roche Holding AG would be worth roughly what it owes.
Total debt $38.25B against a stock market value of $384.81B.
Distance to default 10.59 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $23.09B (short-term plus half of long-term), stock volatility 28.7%; Altman Z'' 4.10. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $38.25B against a stock market value of $384.81B.
Distance to default 10.59 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $23.09B (short-term plus half of long-term), stock volatility 28.7%; Altman Z'' 4.10. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
#1
of 2
Drug Manufacturers - General
Technical Signal Map
9 Bullish
1 Neutral
1 Bearish
RHHBY
$390B
Roche Holding AG
BULLISH
+91
ABBV
$505B
AbbVie Inc.
BULLISH
+100
JNJ
$636B
Johnson & Johnson
BULLISH
+91
PFE
$171B
Pfizer Inc.
BULLISH
+82
NVS
$287B
Novartis AG
BULLISH
+75
GILD
$193B
Gilead Sciences, Inc.
BULLISH
+75
LLY
$1.2T
Eli Lilly and Company
BULLISH
+66
AMGN
$237B
Amgen Inc.
BULLISH
+66
AZN
$266B
AstraZeneca PLC
LEAN BULL
+25
NONOF
$172B
Novo Nordisk A/S
NEUTRAL
-2
MRK
$358B
Merck & Co., Inc.
BEARISH
-68
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| RHHBY Roche Holding AG | $390B | 26.0 | 40.6 | 24.9 | 22.6 | 31.7 | 6 | BULLISH | 42.8 |
| ABBV AbbVie Inc. | $505B | 80.7 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.6 |
| JNJ Johnson & Johnson | $636B | 40.7 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 42.0 |
| PFE Pfizer Inc. | $171B | 39.4 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 20.3 |
| GILD Gilead Sciences, Inc. | $193B | -61.2 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.4 |
| LLY Eli Lilly and Company | $1.2T | 42.9 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 55.5 |
| AMGN Amgen Inc. | $237B | 27.6 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 57.8 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | LEAN BULL | 4.5 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| MRK Merck & Co., Inc. | $358B | 112.6 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 63.5 |
| RHHBY Roche Holding AG | $390B | 26.0 | 40.6 | 24.9 | 22.6 | 31.7 | 6 | BULLISH | 42.8 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.5 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 21.2 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 66.4 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -0.5 |
| UNH UnitedHealth Group Incorporated | $375B | 23.4 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.0 |
| RHHBY Roche Holding AG | $390B | 26.0 | 40.6 | 24.9 | 22.6 | 31.7 | 6 | BULLISH | 42.8 |
| ABBV AbbVie Inc. | $505B | 80.7 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.6 |
| JNJ Johnson & Johnson | $636B | 40.7 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 42.0 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.5 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 21.2 |
| PFE Pfizer Inc. | $171B | 39.4 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 20.3 |
| GILD Gilead Sciences, Inc. | $193B | -61.2 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.4 |
| LLY Eli Lilly and Company | $1.2T | 42.9 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 55.5 |
| AMGN Amgen Inc. | $237B | 27.6 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 57.8 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 66.4 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -0.5 |
| UNH UnitedHealth Group Incorporated | $375B | 23.4 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.0 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | LEAN BULL | 4.5 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| MRK Merck & Co., Inc. | $358B | 112.6 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 63.5 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
RHHBY vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F